News | Antiplatelet and Anticoagulation Therapies | August 16, 2016

Warfarin Use May Not Bring Long-Term Stability for Atrial Fibrillation

Registry study finds INR values fluctuate over 18 months, even in patients considered “stable”

warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney

August 16, 2016 — Warfarin prescribed to prevent strokes in atrial fibrillation may not adequately control blood clotting over the long-term, even when patients have been historically stable on the drug, according to a study from the Duke Clinical Research Institute.

The findings, published Aug. 9 in the Journal of the American Medical Association (JAMA), are based on an 18-month study of 3,749 patients diagnosed with atrial fibrillation, an irregular heart rhythm. The condition is associated with a higher risk of blood clots and stroke, which are avoidable with anticoagulants, a group of drugs that work to thin the blood and prevent clots.

Warfarin, which has an anti-clotting mechanism that targets how the body uses vitamin K, has historically been the only available drug for stroke prevention. However, warfarin can interact negatively with many other drugs and food, and patients on warfarin require regular monitoring.

While costlier than warfarin, non-vitamin K oral anticoagulants (NOACs), which were first approved for use in the United States in 2010, mostly eliminate these drawbacks while often providing similar effectiveness with improved safety.

“For these reasons, the majority of patients who are newly-diagnosed with atrial fibrillation are prescribed NOACs,” said Sean Pokorney, M.D., the study’s first author and an electrophysiology fellow at the Duke University School of Medicine.

“One of the challenges we face as a healthcare community is that there are patients who have been on warfarin for years, and a big question is whether they should be switched to a NOAC,” he said.

To consider this question, Pokorney and co-investigators looked at patients from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, a database maintained by the Duke Clinical Research Institute. Patients were eligible to participate in the study if they were taking warfarin. Then, researchers focused on a measure of blood thinness called the international normalized ratio (INR).

For patients on warfarin, INR is typically measured monthly and ideally falls between 2 and 3. During the study’s first six months, 968 patients (26 percent of those taking warfarin) had 80 percent or more of their INR values fall in this range and 376 patients (10 percent of warfarin patients) had 100 percent of their INR values fall in this range.

Over an additional 12 months, these patients were monitored and considered “stable” if 80 percent or more of their INR values were between 2 and 3.

Among patients in the 80 percent group, 34 percent remained stable during the subsequent year. Among patents in the 100 percent group, 37 percent had stability over the next year.

“What these results essentially tell us is that patients’ past performance on warfarin doesn’t predict their future performance,” Pokorney said. “Just because patients have done well on warfarin in the past doesn’t mean they will continue to do well, and so it does call into question whether it is appropriate to switch them to a NOAC.”

The study also found that about a third of patients in both the 80 percent and 100 percent groups had one or more INR values that were well out of the ideal range during the subsequent year. Pokorney said this finding is important because risk of clotting and stroke increases most significantly when INR falls below 1.5 and risk of brain bleeding increases dramatically when INR rises above 4.

“It’s not appropriate for every patient to be treated with a NOAC, but this study shows that all patients eligible for a NOAC, even those who have done well on warfarin in the past, should have a shared decision-making conversation with their healthcare provider about considering a change,” Pokorney said.

In addition to Pokorney, study authors include DaJuanicia N. Simon, Laine Thomas, Bernard J. Gersh, Elaine M. Hylek, Jonathan P. Piccini and Eric D. Peterson.

Janssen Scientific Affairs provided funding for the patient registry and data analysis. The author’s disclosures are available in the study’s manuscript, which is available upon request.

Read the article “Advantages and Disadvantages of Novel Oral Anticoagulants.”
 

For more information: www.jama.jamanetwork.com

Related Content

News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Subscribe Now